HAEMATO AG (HAM: HAEK)

Market Cap	58.03M
Revenue (ttm)	260.81M
Net Income (ttm)	9.61M
Shares Out	5.23M
EPS (ttm)	1.88
PE Ratio	5.92
Forward PE	n/a
Dividend	0.04 (0.36%)
Ex-Dividend Date	Jul 17, 2024

Volume	742
Open	10.60
Previous Close	10.80
Day's Range	10.60 - 10.60
52-Week Range	10.20 - 20.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 9, 2024

About HAEMATO AG

HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. Further, the company develops, manufactures, and distributes diagnostic tests under the HAEMATO...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 1993
• Employees: 76
• Stock Exchange: Hamburg Stock Exchange
• Ticker Symbol: HAEK

Financial Performance

In 2022, HAEMATO AG's revenue was 248.14 million, a decrease of -12.95% compared to the previous year's 285.04 million. Earnings were 8.19 million, an increase of 25.39%.